Last reviewed · How we verify
TK-254RX
At a glance
| Generic name | TK-254RX |
|---|---|
| Sponsor | Teikoku Seiyaku Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- To Evaluate the Adhesion of TK-254RX on Healthy Participants (PHASE1)
- Phase III Trial to Evaluate the Efficacy and Safety in Patients With Ankle Sprains. (PHASE3)
- Phase III Trial to Assess the Safety and Efficacy of TK-254RX in Patients With Contusions (PHASE3)
- To Assess the Effect of the Special Condition on the Pharmacokinetics and Tolerability of the Esflurbiprofen Topical System (EFTS) in Healthy Volunteers. (PHASE1)
- To Assess the Bioavailability of TK-254RX in Comparison with Oral Flurbiprofen Tablets and the Adhesion of TK-254RX in Healthy Subjects (PHASE1)
- Open Label Trial to Evaluate the Adhesion of TK-254RX in Healthy Volunteers. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TK-254RX CI brief — competitive landscape report
- TK-254RX updates RSS · CI watch RSS
- Teikoku Seiyaku Co., Ltd. portfolio CI